iBio, Inc. (NYSEAMERICAN:IBIO) Sees Large Growth in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 184,500 shares, an increase of 14.1% from the March 31st total of 161,700 shares. Based on an average trading volume of 3,720,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.2% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of iBio in a report on Wednesday, March 27th. They issued a “sell” rating for the company.

iBio Stock Performance

Shares of NYSEAMERICAN:IBIO traded down $0.10 during mid-day trading on Monday, hitting $1.66. The stock had a trading volume of 292,887 shares, compared to its average volume of 2,971,024. iBio has a 12-month low of $1.02 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91.

iBio (NYSEAMERICAN:IBIO) last posted its quarterly earnings results on Friday, February 9th. The company reported ($2.42) earnings per share for the quarter.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.